AllianceBernstein
CELGZ

AllianceBernstein’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

AllianceBernstein’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-7,090
Closed -$53K – 3586
2013
Q2 		$53K Buy
+7,090
New +$51.4K ﹤0.01% 2991

Other funds holding CELGZ

ACM
Ayer Capital Management San Francisco, California $26.8M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
Pomelo Capital New York $1.04B AUM 1.25% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
FANJ
Financial Architects (New Jersey) Marlton, New Jersey $663M AUM 15.53% 1-Year Est. Return

AllianceBernstein's CELGZ Position: Q3 2013 in Review

AllianceBernstein sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q3 2013, closing a stake of 7,090 shares — an estimated $53K sold.

AllianceBernstein first reported a position in CELGZ in Q2 2013 and held it in 1 quarter. The position peaked at $53K in Q2 2013. 26 funds tracked by Wall St. Rank hold CELGZ as of Q3 2013.

  • AllianceBernstein reported no remaining Celgene Corporation Contingent Value Rights position as of Q3 2013 after selling out during the quarter.
  • AllianceBernstein sold 7,090 Celgene Corporation Contingent Value Rights shares in Q3 2013, an estimated $53K.
  • AllianceBernstein first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 1 quarter.
  • AllianceBernstein's Celgene Corporation Contingent Value Rights position peaked at $53K in Q2 2013.
  • 26 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q3 2013.

Based on AllianceBernstein's 13F filing for Q3 2013, filed 14 Nov 2013.